A1C and BMI Changes by Sociodemographic Groups Among Patients UsingGLP-1 Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors(SGLT-2i) in a Large Integrated Health System
by Prateek Chopra | June 23, 2026 | Diabetes Conferences | ADA 2026 | 0 comments Clinical Relevance Methods Study Population Glycemic and Weight Outcomes Differences Across Demographic Groups Clinical Implications In a real-world healthcare setting, GLP-1 RA therapy was associated with clinically meaningful reductions in HbA1c and BMI among patients with T2DM and obesity. Greater benefits observed in specific racial, ethnic,